Latest news with #GMP-compliant
Miami Herald
3 days ago
- Business
- Miami Herald
Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward
President and COO Judy Murrah Appointed New Chairperson of the Board of Directors and CEO STONY BROOK, NY / ACCESS Newswire / June 17, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that Chairperson and Chief Executive Officer Dr. James A. Hayward is retiring from the Company and will step down from the Board of Directors effective June 18, 2025, following a distinguished 20-year term. During his tenure, Dr. Hayward was instrumental in transforming the Company's proprietary DNA production and detection technologies into commercial platforms, thereby establishing the foundation for Applied DNA's current market offerings. Furthermore, the Board of Directors of Applied DNA has appointed Judy Murrah to the roles of Chairperson, Board Director, and Chief Executive Officer in addition to retaining her current position as President. Ms. Murrah will lead the executive management team, which comprises Clay Shorrock, Chief Legal Officer and President of LineaRx, the Company's biotherapeutics subsidiary, and Beth Jantzen, Chief Financial Officer. With over a decade of operational leadership at Applied DNA, Ms. Murrah has been influential in driving product commercialization, business scaling, and, more recently, the launch of the Company's GMP-compliant DNA manufacturing capabilities. She was previously with Symbol Technologies ("Symbol"), where she played key roles in the company's growth from an early-stage company to an enterprise with approximately $2 billion in revenue and 5,000 employees, holding successive Vice President positions across Sales, Marketing, and Information Technology. Following Symbol's acquisition by Motorola, Inc. ("Motorola"), she held strategic leadership roles at Motorola, overseeing critical financial management, quality, and program management initiatives during significant business transformations, mergers, acquisitions, and divestitures. Ms. Murrah is an inventor on 14 U.S. patents and holds an MBA from Harvard Business School. Board Director Robert C. Catell stated, "On behalf of all the employees of the Company and the Board of Directors, I offer sincere thanks to Jim for his many years of scientific innovation, personal contribution, and passion he brought to Applied DNA. His accomplishments and impact are wide-ranging and will endure with the Applied DNA team and the local Long Island community." Continued Mr. Catell, "Judy has played an increasingly key role in recent years and has helped to grow who we are today as a company. Applied DNA is poised for opportunity with an established biotherapeutic manufacturing capability that we believe is proven to address the manufacturing challenges identified by the industry. Driving it to deployment and scale with customers, partners, and regulators is our next mission, and the Board is confident that Judy's leadership will put the Company on the best path forward to maximize long-term shareholder value." Added Ms. Murrah, "I am honored to take on the Chairperson and CEO roles and lead our associates and Applied DNA forward at this important inflection point, as we focus on our most promising aspects of our businesses, drive increased operating efficiency, and navigate the current macro environment." About Applied DNA Sciences Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we operate in two business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; and (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services. Visit for more information. Follow us on X and LinkedIn. Forward-Looking Statements The statements made by Applied DNA in this press release may be "forward-looking" in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA's future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. These forward-looking statements are based largely on the Company's expectations and projections about future events and future trends affecting our business and are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including statements regarding the ability of Ms. Judy Murrah to successfully replace Dr. James Hayward as Chairperson and CEO of the Company, its goal to position the Company for long term-growth and value creation and the potential to achieve that goal and the future success of its Linea DNA and Linea IVT platforms.. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, substantial doubt regarding its ability to continue as a going concern, unknown future demand for its biotherapeutics products and services, the unknown amount of revenues and profits that will result from our Linea IVT and/or Linea DNA platforms, the fact that there has never been a commercial drug product utilizing the LineaDNA and/or IVT platforms approved for therapeutic use, the ability of the Company's common stock to remain listed on Nasdaq as well as various other factors detailed from time to time in Applied DNA's SEC reports and filings, including its Annual Report on Form 10-K filed on December 17, 2024, its Quarterly Reports on Form 10-Q filed on February 13, 2025, and May 15, 2025, and other reports it files with the SEC, which are available at Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law. Applied DNA Sciences Contact: Investor Relations contact: Sanjay M. Hurry, 917-733-5573, Web: SOURCE: Applied DNA Sciences, Inc.
Business Wire
13-06-2025
- Business
- Business Wire
Ethris Signs Strategic Collaboration with Thermo Fisher Scientific to Provide Access to mRNA Technology Platforms
MUNICH--(BUSINESS WIRE)-- Ethris GmbH, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to provide a fully integrated mRNA solution to biopharmaceutical developers. The collaboration brings together Ethris' comprehensive mRNA technology platforms, including its proprietary Stabilized Non-Immunogenic mRNA (SNIM ® RNA), minimal UTR and mRNA manufacturing technologies with Thermo Fisher's industry-leading end-to-end GMP-compliant manufacturing capabilities. Broadening global access to Ethris' comprehensive suite of mRNA technology platforms, the partners will facilitate the ability of biopharmaceutical developers to rapidly advance candidate mRNA medicines from research to clinical proof-of-concept. 'Thermo Fisher Scientific has a long-standing track record of supporting the development of advanced therapies,' said Dr. Carsten Rudolph, CEO of Ethris. 'By combining our clinically validated mRNA platforms with Thermo Fisher's manufacturing expertise, we are creating a powerful offering for biopharma partners. This collaboration addresses the increasing demand for scalable, high-quality mRNA technologies and enables us to serve a broader set of collaborators worldwide.' The collaboration will also support the continued optimization of Ethris' platform technologies, which have already demonstrated positive pharmacodynamic effects, safety and targeted engagement in Phase 1 topline data of its lead candidate, ETH47. Designed for local administration via nasal spray to address the upstream trigger of asthma exacerbations, ETH47 showed dose-dependent, localized production of the encoded protein, interferon lambda at the site of administration, with no systemic bioavailability. The study confirmed that ETH47 activated downstream signaling, demonstrating the expressed protein's functional activity. Given its non-immunogenic nature, SNIM® RNAs can be administered repeatedly, leading to sustained production of therapeutically active proteins within the human body. Eligible for multiple routes of administration, the technology can replace or augment missing or non-functional proteins that cause a disease, introduce new proteins to modulate the course of the disease or its symptoms and be used to develop vaccines. 'Thermo Fisher is committed to supporting the rapid translation of breakthrough therapies into clinical application,' said Ben Castro, Vice President and General Manager, Large Molecule, Drug Substance, Thermo Fisher Scientific. 'By partnering with Ethris, we are expanding our services to include cutting-edge mRNA manufacturing, empowering our customers to bring life-changing treatments to patients faster and more efficiently.' Ethris' SNIM® RNA platform sets new standards for mRNA therapeutics by enabling safe, efficacious and stable drug products as well as scalable manufacturing, expanding the potential of mRNA medicines. About Ethris Ethris, a clinical-stage biotechnology company, has paved a new path from genes to therapeutic proteins, using its proprietary RNA and lipidoid nanoparticle technology platform to discover, design and develop innovative therapies. With more than a decade as an mRNA pioneer, Ethris is a global leader in delivering stabilized mRNAs directly to the respiratory system via optimised formulation and nebulisation technologies. The company is rapidly advancing its mRNA pipeline of immuno-modulation, protein replacement therapies, and differentiated vaccines, with the ultimate goal of improving patients' lives. For more information, visit
Fibre2Fashion
10-06-2025
- Business
- Fibre2Fashion
Hubergroup opens India's first DFC ink facility in Silvassa
With the inauguration of India's first dedicated production facility for Direct Food Contact (DFC) inks, hubergroup Print Solutions reached another significant milestone in May. The state-of-the-art facility in Silvassa is entirely separated from other production areas, setting new standards in safety, sustainability, and innovation for food packaging. hubergroup, a leading expert in printing inks and speciality chemicals, thereby not only strengthens its position in the international market but also supports local businesses with global-quality solutions. Hubergroup inaugurated India's first dedicated Direct Food Contact (DFC) ink facility in Silvassa, producing safe, sustainable MGA CONTACT inks for direct food packaging. GMP-compliant plant boosts local supply, supports eco-friendly paper-based solutions, and reinforces Hubergroup's global leadership in innovative, food-safe packaging inks. The new facility produces the sheet-fed ink series MGA CONTACT, specifically developed for direct contact with food. These inks comply with stringent international safety standards and allow printing on the inside of paper and cardboard packaging, when coated with a dispersion varnish such as hubergroup's ACRYLAC DFC series. This opens up new design possibilities for packaging products like chocolates, fruits, and fast food, supporting the transition to more environmentally friendly, paper-based solutions. Safe, sustainable and innovative packaging All raw materials used in the production are thoroughly screened, and the final inks undergo strict quality controls. The production adheres to Good Manufacturing Practice (GMP) principles and is designed to minimize carbon footprint and utilize renewable materials. 'We are very delighted about this inauguration, as it establishes us as a frontrunner in the Indian market,' says Prasanta Sarkar, Vice President, Technology Print Solution at hubergroup India. 'The mission of the new facility is clear: to make packaging safer, more sustainable, and more innovative. Our DFC inks and varnishes meet strict global safety standards and are designed with both people and the planet in mind.' Global significance for hubergroup and its customers 'This achievement is the result of tireless efforts by our global R&D teams, our partners, and colleagues who believed in this vision. We are proud to have implemented this world-class technology in India, supporting local businesses with global-quality solutions,' says Premal Desai, CEO at hubergroup. The inauguration of this specialized production facility in Silvassa underscores hubergroup's commitment to innovation and sustainability in the packaging industry. As a strategically important site within the company's global network, the facility contributes to increased supply security and offers tailored solutions to customers worldwide. Note: The headline, insights, and image of this press release may have been refined by the Fibre2Fashion staff; the rest of the content remains unchanged. Fibre2Fashion News Desk (HU)
Business Wire
09-06-2025
- Business
- Business Wire
CGT Global Supports Renown Health in Advancing Breast Cancer Treatment in Nevada
RENO, Nev.--(BUSINESS WIRE)--CGT Global, a leader in cell and gene therapy access, is proud to announce their support for the Conrad Breast Center at Renown South Meadows Medical Center in Reno, Nevada. As part of CGT's contribution, the Center's Pharmacy Office will carry the 'CGT Global' name. The financial contribution, made on behalf of CGT Global, our clients, and industry partners, reflects our mission to expand access to life-changing treatments. We are honored to support Renown Health's vision and help bring next-generation care to Nevada. 'Our support for Renown Health reflects CGT Global's broader vision to bring cutting-edge therapies from the lab bench to the bedside,' said Cate Spears, CEO & Founder of CGT Global. 'We believe scientific breakthroughs must translate into real-world impact. We love that the new breast cancer center will provide more fully integrated and multidisciplinary access to treatment across the region.' The Conrad Breast Center will offer comprehensive services such as imaging, counseling for patients with increased risk for developing cancer , breast surgical oncology, medical oncology, radiation oncology, infusion therapy, evidence-based wellness medicine, and clinical research. The Center opened last week, and promises world-class, patient-centered care. Renown Health's Pennington Cancer Institute has been recognized among the top 100 cancer programs in the US by Becker's Hospital Review. CGT Global will continue to support organizations with a shared commitment to delivering cutting-edge therapies to local communities. Our support reflects our ongoing mission to enable emerging treatments like cell and gene therapy—powerful tools in the long-term fight against cancer. We believe that strong partnerships will help lead a new era of personalized medicine—grounded in science, community, and care. About CGT Global CGT Global is a biotechnology company advancing access to cell and gene therapies. With a national network of clinical sites and laboratories, CGT Global delivers high-quality biospecimens, GMP-compliant manufacturing, and end-to-end support to accelerate therapeutic development. Headquartered in Folsom, CA, CGT Global partners with top pharmaceutical companies, CROs, and hospitals. Learn more at
Business Upturn
07-06-2025
- Health
- Business Upturn
Super Feels Kava Kratom Shot Announces Official Website Update Featuring Natural Daily Supplement for Mood and Relaxation Support
FORT LAUDERDALE, June 07, 2025 (GLOBE NEWSWIRE) — Super Feels Kava Kratom Shot, a plant-based wellness solution developed by Super Speciosa, has updated its official website to share new information about its daily supplement formulated to support mood balance and natural relaxation in adults. Now available across the U.S., the convenient liquid shot is designed for individuals seeking a natural, on-the-go wellness solution rooted in traditional botanicals. According to the official product website ( Super Feels is intended to work in harmony with the body's systems to support a sense of calm and well-being through its unique combination of kratom leaf extract and noble kava root. The company positions the product as a ready-to-use formula that easily integrates into modern lifestyles without the need for pills or powders. 'We wanted to create something portable, natural, and approachable—something people can use to help manage life's daily stressors in a more mindful way,' said a spokesperson for Super Speciosa. 'This product reflects our commitment to clean formulation and botanical tradition.' The company states that Super Feels Kava Kratom Shot is manufactured in GMP-compliant facilities that prioritize rigorous quality control and ingredient sourcing. It is crafted to meet the needs of adults seeking a plant-based option to support relaxation and mental clarity without artificial additives. As noted on the product website, Super Feels includes a satisfaction guarantee for first-time buyers. Those interested in exploring the formulation's functional use cases or ordering directly can access detailed information, customer FAQs, and secure checkout at the official site. About Super Feels by Super Speciosa Super Feels is part of Super Speciosa, a Florida-based wellness brand dedicated to premium kratom and herbal-based solutions. With a focus on transparency and natural sourcing, the company creates functional plant-based products that support modern wellness goals. Product and Contact Information Brand: Super Feels by Super Speciosa Website: Email: [email protected] Phone: +1 (888) 958-5401 Mailing Address: 727 NE 3rd Ave, Suite 201, Fort Lauderdale, FL 33304, USA Disclaimer This release is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. The statements made about this product have not been evaluated by the Food and Drug Administration. Individual results may vary. Consumers should consult a qualified healthcare provider before beginning any new dietary supplement. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
